Fig. 5From: Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in ItalyResults of probabilistic sensitivity analysis: cost effectiveness acceptability curveBack to article page